Likewise, in the large, randomized, phase 3 trial (AGILE) of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed IDH1 mutated AML, the incidence of DS in the placebo arm was 8% (six patients) [74]. Here, IDH1 is linked to acute myeloid leukemia.